SI-BONE, Inc. - Common Stock (SIBN)
Frequently Asked Questions About SI-BONE, Inc. - Common Stock (SIBN)
How can investors learn more about SI-BONE, Inc.?
Investors can learn more about SI-BONE, Inc. by visiting the company’s investor relations website, reviewing its financial reports and SEC filings, and following its updates on market performance and product launches.
How does SI-BONE, Inc. approach sustainability?
SI-BONE, Inc. approaches sustainability by implementing eco-friendly practices in product development and manufacturing, aligning with industry standards that promote environmental responsibility and reduce waste.
How does SI-BONE, Inc. contribute to patient care?
SI-BONE, Inc. contributes to patient care by providing innovative, effective, and minimally invasive treatment options for individuals suffering from sacroiliac joint pain. Their products aim to reduce recovery times and improve patient outcomes.
How does SI-BONE, Inc. handle regulatory compliance?
SI-BONE, Inc. works closely with regulatory bodies such as the FDA to ensure all its products meet safety and efficacy standards. The company engages in rigorous clinical testing and follows established protocols for product approval.
Is SI-BONE, Inc. publicly traded?
Yes, SI-BONE, Inc. is publicly traded on the NASDAQ stock exchange under the ticker symbol SIBN, allowing investors to buy shares and participate in the company's growth.
What are the competitive advantages of SI-BONE, Inc.?
SI-BONE, Inc.'s competitive advantages include its innovative product designs, a strong patent portfolio, clinical evidence supporting its technology, and a dedicated focus on the sacroiliac joint market.
What does SI-BONE, Inc. do?
SI-BONE, Inc. focuses on developing innovative medical devices for the treatment of sacroiliac joint disorders, which are conditions affecting the joint connecting the spine to the pelvis. The company has developed a range of products designed to provide minimally invasive surgical solutions, helping patients manage pain and improve mobility.
What is sacroiliac joint dysfunction?
Sacroiliac joint dysfunction refers to pain that originates from the sacroiliac joint, which may occur due to injury, arthritis, or other conditions. This dysfunction can cause significant discomfort and mobility issues, making effective treatment essential.
What is the company's commitment to education?
SI-BONE, Inc. is committed to continuous education and training for surgeons to ensure optimal outcomes with its products. The company provides resources, workshops, and seminars to keep medical professionals informed on new techniques and product innovations.
What is the iFuse Implant System?
The iFuse Implant System is a minimally invasive surgical system developed by SI-BONE for the treatment of sacroiliac joint dysfunction. It uses a series of implants to stabilize the joint and promotes fusion, helping to alleviate pain associated with sacroiliac joint disorders.
What is the outlook for SI-BONE, Inc. in the coming years?
The outlook for SI-BONE, Inc. is positive, as the demand for minimally invasive surgical options is growing, and the company continues to innovate and expand its product lines to meet the needs of the healthcare market.
What is the target market for SI-BONE, Inc. products?
SI-BONE, Inc. primarily targets orthopedic and neurosurgical surgeons and their patients who are suffering from sacroiliac joint pain, serving a growing population in need of effective treatment solutions.
What is the vision of SI-BONE, Inc.?
The vision of SI-BONE, Inc. is to be a leader in spinal innovation, focusing on developing advanced technologies that improve patient care and outcomes associated with sacroiliac joint disorders.
What recent achievements has SI-BONE, Inc. accomplished?
Recently, SI-BONE, Inc. has achieved significant milestones, including expanding its product offerings, receiving positive clinical trial results, and increasing market penetration for its iFuse Implant System.
What research and development does SI-BONE, Inc. conduct?
SI-BONE, Inc. invests significantly in research and development to advance its product offerings and explore new treatment methodologies for sacroiliac joint disorders, ensuring that it remains at the forefront of medical device innovation.
What role do clinical studies play in SI-BONE, Inc.?
Clinical studies are integral to SI-BONE, Inc.'s strategy, as they provide essential data to validate the safety and efficacy of its products. These studies help inform product development and ensure compliance with healthcare regulations.
What type of products does SI-BONE, Inc. offer?
SI-BONE, Inc. offers a range of proprietary implants and instrumentation for the treatment of sacroiliac joint disorders, including the iFuse Implant System, which is designed for minimally invasive surgical stabilization of the sacroiliac joint.
When was SI-BONE, Inc. founded?
SI-BONE, Inc. was founded in 2008, with the mission of addressing the challenges associated with sacroiliac joint dysfunction and solving significant clinical needs through innovative spine-focused solutions.
Where is SI-BONE, Inc. headquartered?
SI-BONE, Inc. is headquartered in Santa Clara, California, where it strategically positions itself within one of the key regions for medical device innovation and development.
Who are the key executives at SI-BONE, Inc.?
The key executives at SI-BONE, Inc. include the CEO, CFO, and various heads of departments focused on product development, marketing, and regulatory affairs. These leaders bring a wealth of experience in the medical device industry.
What is the current price of SI-BONE, Inc. - Common Stock?
The current price of SI-BONE, Inc. - Common Stock is 19.79
When was SI-BONE, Inc. - Common Stock last traded?
The last trade of SI-BONE, Inc. - Common Stock was at 4:00 pm EDT on May 16th, 2025
What is the market capitalization of SI-BONE, Inc. - Common Stock?
The market capitalization of SI-BONE, Inc. - Common Stock is 658.43M
How many shares of SI-BONE, Inc. - Common Stock are outstanding?
SI-BONE, Inc. - Common Stock has 33.27M shares outstanding.